

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
ENP-031

In Re Application Of: Or, et al.

FEB 20 2003

Serial No.  
09/975,923

Filing Date  
10/12/2001

Examiner  
Samuel W. Liu

Group Art Unit  
1653

Title: Cyclosporin Analogs for the Treatment of Lung Diseases

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

RECEIVED  
FEB 26 2003  
TECH CENTER 1600/2900

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(p) or 1.97(c))

Docket No.  
ENP-031

In Re Application: Or, et al.

FEB 20 2003

Serial No.

09/975,923

Filing Date

10/12/2001

Examiner

Samuel W. Liu

Group Art Unit

1653

Cyclosporin Analogs for the Treatment of Lung Diseases

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-2010 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$180.00
  - ☒ Credit any overpayment.
  - ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited 2/13/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Stacie S. Capotosto

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Jason D. Ferrone  
Reg. No. P-57,887

Dated: 02/13/2003

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

02/24/2003 HMARZI1 00000008 502010 09975923

01 FC:1806

180.00 CH

CC:

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

FEB 20 2003

Docket Number (Optional)

ENP-031

Application Number

09/975,923

Applicant(s)

Or, et al.

Filing Date

10/12/2001

Group Art Unit

1653

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	US 4,554,351	11/19/1985	Wenger	544	177	5/5/1983
	AB	US 4,798,823	1/17/1989	Witzel	514	11	6/3/1987

RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Faulds et al., Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders, Drugs 46, 953-1040 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.